NRC Health Reports First YoY Revenue Growth Since 2023, Record TRCV, and Strong Cash Flow in Q1
NRC sits 60% above its 52-week low of $10.524.
Summary
NRC Health announced its first quarter 2026 results, highlighting its first year-over-year revenue growth since 2023, record Total Recurring Contract Value, and increased cash flow from operations, despite a decline in net income.
Key Events · Earnings and Guidance · NRC
-
First Year-over-Year Revenue Growth Since 2023
Total revenue for Q1 2026 was $34.8 million, marking a 4% increase from the prior year and the first year-over-year growth since 2023.
-
Record Total Recurring Contract Value (TRCV)
TRCV reached a record $152.1 million, up 13% year-over-year, representing the sixth consecutive quarter of sequential growth.
-
Signed Largest Deal in Company History
The company announced the signing of the largest deal in its 45-year history, validating its strategic direction and value proposition.
-
Improved Cash Flow from Operations
Net cash flow from operating activities increased 8% year-over-year to $7.2 million, with free cash flow rising to $5.4 million.
Analysis · NRC · Industrial Applications And Services
NRC Health's first quarter 2026 results present a mixed financial picture but highlight significant operational momentum. While GAAP net income and earnings per share declined year-over-year, the company achieved its first year-over-year revenue growth since 2023 and reported record Total Recurring Contract Value (TRCV), indicating a potential turnaround in its growth trajectory. The CEO's announcement of the largest deal in the company's 45-year history further underscores strong operational execution and future revenue potential. Additionally, improved cash flow from operations provides a solid financial foundation. Investors should monitor if this operational strength translates into sustained profitability in upcoming quarters.
At the time of this filing, NRC was trading at $16.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $383M. The 52-week trading range was $10.52 to $22.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.